Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12534300 | 0.98 | KMT2A (0.50) | HSP90AA1POLBKMT2ASMN1; SMN2ALDH1A1 | |
| Bromide SCHEMBL9080240 | 0.96 | KMT2A (0.53) | HSP90AA1POLBKMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL19031290 | 0.82 | KMT2A (0.47) | HSP90AA1POLBKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL19037381 | 0.79 | KMT2A (0.48) | HSP90AA1POLBKMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL624259 | 0.79 | KMT2A (0.46) | HSP90AA1POLBKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21665861 | 0.77 | KMT2A (0.47) | HSP90AA1POLBKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8971406 | 0.77 | TSHR (0.48) | HSP90AA1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL4232151 | 0.77 | KMT2A (0.47) | HSP90AA1POLBKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10123563 | 0.76 | KMT2A (0.45) | HSP90AA1POLBKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3771803 | 0.76 | KMT2A (0.45) | HSP90AA1POLBKMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026326-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1506186-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003099808-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-0655997-B1 | PYRIDINIUM INTERMEDIATES AND THE PROCESS FOR PREPARING THE SAME | ABBOTT LAB (US) | 1997-02-12 | — | — | EP | disclosed |
| EP-0655997-A1 | PYRIDINIUM INTERMEDIATES AND THE PROCESS FOR PREPARING THE SAME. | ABBOTT LAB (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0655997-A4 | PYRIDINIUM INTERMEDIATES AND THE PROCESS FOR PREPARING THE SAME. | ABBOTT LAB (US) | 1995-02-10 | — | — | EP | disclosed |
| US-5294721-A | Reacting a halonitrobenzene and a pyridinium salt | ABBOTT LABORATORIES (US) | 1994-03-15 | — | — | US | disclosed |
| WO-1994004502-A1 | PYRIDINIUM INTERMEDIATES AND THE PROCESS FOR PREPARING THE SAME | ABBOTT LABORATORIES (US) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | ACHE 294/4885HSP90AA1 719/4885POLB 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.